Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9934908 | 0.88 | IKBKB (0.31) | SLC29A1KMT2ATHRB | |
| SCHEMBL9934702 | 0.78 | TAAR1 (0.31) | — | |
| SCHEMBL600149 | 0.78 | SLC29A1 (0.48) | SLC29A1KMT2ATHRBPDE10AALDH1A1 | |
| SCHEMBL19166260 | 0.77 | SLC29A1 (0.42) | SLC29A1KMT2ATHRBPDE10AALDH1A1 | |
| SCHEMBL9934511 | 0.76 | THRB (0.36) | SLC29A1KMT2ATHRBPDE10AALDH1A1 | |
| SCHEMBL9935470 | 0.76 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL9933471 | 0.76 | HTT (0.33) | HTT | |
| SCHEMBL9934508 | 0.75 | NCF1 (0.35) | ALDH1A1 | |
| SCHEMBL9934524 | 0.75 | HTR1B (0.34) | — | |
| SCHEMBL25029270 | 0.74 | KMT2A (0.51) | SLC29A1KMT2ATHRBPDE10AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| EP-2518060-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | SLC29A1 3210/4885KMT2A 3600/4885THRB 195/4885 |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | SLC29A1 2915/4885KMT2A 3915/4885THRB 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.